Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. The lead program features innovative antibody design as well as state of the art linker and payload technology to target Nectin-4 – an important and validated target for a broad range of cancers.
![ETX LOGO HORIZEMAIL6cm (002)](https://hadeanventures.com/wp-content/uploads/2021/12/ETX-LOGO-HORIZEMAIL6cm-002-2-300x53.png)
Year of investment
2021
Sector
Drug development
Location
Duisburg, Germany
Website
http://emergencetx.com/